Development of an inhaled liposomal-loaded azithromycin formulation for the treatment of chronic respiratory infection

Long term antibiotics are commonly prescribed in these conditions to decrease exacerbation frequency and improve quality of life. Azithromycin is often given orally for this purpose with its benefit thought to be due to a dual antibacterial and anti-inflammatory effect.

In this thesis, the aim was to develop an inhaled liposomal loaded azithromycin formulation that could be delivered via dry powder inhaler for use in chronic lung infection. By delivering the antibiotic directly to the site of action in the lungs, higher local concentrations could be achieved whilst overcoming issues with oral therapy such as systemic side effects and the exposure of bacteria at non-target sites. Furthermore, the encapsulation of azithromycin within liposomes should offer advantages in both sputum and bacterial biofilm penetration. <br><br>Results from this study showed the formulation could be manufactured reproducibly, with good stability retained following one-year storage.